EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

In vivo engineering of T cells with a synthetic cytokine receptor enables selective enrichment and expansion of anti-CD22 CAR T cells

Travis J Friesen, Alyssa Sheih, Nikole Perdue, Nolan G Ericson, Dillon Jarrell, Ashley M Yingst, Christopher J Nicolai, Timothy Gervascio, Seungjin Shin, Jessica Freeman, Laurie O Beitz, Samantha D O'Hara und 4 weitere

Molecular Therapy · 2026-10 · 34 (10) · 5783-5795

DOI: 10.1016/j.ymthe.2026.08.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2026-10. Verfasst von Travis J Friesen und 15 weiteren Autor:innen. Beteiligte Einrichtung: Umoja Biopharma, Seattle, WA 98109, USA. Hauptthemen laut MEDLINE: Sialic Acid Binding Ig-like Lectin 2, Receptors, Chimeric Antigen, T-Lymphocytes, Immunotherapy, Adoptive. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ex vivo-manufactured chimeric antigen receptor (CAR) T cells targeting CD19 have transformed treatment strategies for patients with B cell malignancies and have shown promising results in autoimmune disease. Yet despite their success, significant barriers remain that impede patient access to these therapies, including their complex manufacturing and the need for lymphodepleting chemotherapy. Moreover, many patients who receive ex vivo-manufactured CD19 CAR T cells do not achieve durable responses, suggesting that the expansion and persistence of CAR T cells may need improvement, and/or that strategies targeting alternative antigens may be needed for patients who are refractory to or relapse following treatment with CD19-directed therapies. Umoja is developing a surface-engineered lentiviral vector platform capable of generating CAR T cells in vivo without lymphodepletion. UB-VV400 delivers a payload composed of a fully human anti-CD22 CAR and the rapamycin-activated cytokine receptor (RACR), which enable preferential expansion and enrichment of CAR T cells in response to rapamycin. Here, we describe preclinical studies demonstrating that UB-VV400 generates anti-CD22 CAR T cells that kill CD22-expressing B cells and tumor cells in vitro and in vivo, and that engagement of RACR results in the selective expansion and enrichment of CAR T cells in vivo leading to complete tumor clearance and B cell depletion.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sialic Acid Binding Ig-like Lectin 2Receptors, Chimeric AntigenT-LymphocytesImmunotherapy, AdoptiveReceptors, CytokineReceptors, Antigen, T-CellHumansAnimalsAntigens, CD19MiceLentivirusGenetic VectorsXenograft Model Antitumor AssaysCell Line, Tumor

Stichwörter der Autor:innen

B cell malignanciesCD22in vivo CAR Tsynthetic cytokine receptor

Substanzen

Sialic Acid Binding Ig-like Lectin 2Receptors, Chimeric AntigenAntigens, CD19Receptors, CytokineReceptors, Antigen, T-CellCD22 protein, human

Autor:innen und Institutionen

  • Umoja Biopharma, Seattle, WA 98109, USA.
  • Umoja Biopharma, Louisville, CO 80027, USA.
  • Umoja Biopharma, Seattle, WA 98109, USA. Electronic address: jeff.teoh@umoja-biopharma.com.

Zitieren

APA

Friesen, T. J., Sheih, A., Perdue, N., Ericson, N. G., Jarrell, D., Yingst, A. M., Nicolai, C. J., Gervascio, T., Shin, S., Freeman, J., Beitz, L. O., O'Hara, S. D., Sullivan, A. M., Brandes, A. H., Larson, R. P., & Teoh, J. J. (2026). In vivo engineering of T cells with a synthetic cytokine receptor enables selective enrichment and expansion of anti-CD22 CAR T cells. Molecular Therapy, 34(10), 5783-5795. https://doi.org/10.1016/j.ymthe.2026.08.003

Vancouver

Friesen TJ, Sheih A, Perdue N, Ericson NG, Jarrell D, Yingst AM, et al. In vivo engineering of T cells with a synthetic cytokine receptor enables selective enrichment and expansion of anti-CD22 CAR T cells. Molecular Therapy. 2026;34(10):5783-5795. doi:10.1016/j.ymthe.2026.08.003

BibTeX
@article{Friesen2026,
  author = {Friesen, Travis J and Sheih, Alyssa and Perdue, Nikole and Ericson, Nolan G and Jarrell, Dillon and Yingst, Ashley M and Nicolai, Christopher J and Gervascio, Timothy and Shin, Seungjin and Freeman, Jessica and Beitz, Laurie O and O'Hara, Samantha D and Sullivan, Alessandra M and Brandes, Alissa H and Larson, Ryan P and Teoh, Jeffrey J},
  title = {In vivo engineering of T cells with a synthetic cytokine receptor enables selective enrichment and expansion of anti-CD22 CAR T cells},
  journal = {Molecular Therapy},
  year = {2026},
  volume = {34},
  number = {10},
  pages = {5783--5795},
  doi = {10.1016/j.ymthe.2026.08.003}
}
Kostenlos starten →